舒利迭吸入对中重度COPD患者的疗效观察

目的观察舒利迭（50/500μg）在慢性阻塞性肺疾病（COPD）缓解期中的疗效。方法确诊的中重度COPD患者46例,随机分为治疗组和对照组。对照组给予茶碱缓释片0.2,bid,万托林2～3喷,tid;治疗组给予吸入舒利迭（50/500μg）,bid。结果治疗组在观察期间临床症状、肺功能较对照组明显改善、急性发作次数明显低于对照组。结论在中重度COPD缓解期中应用舒利迭能提高患者肺功能,明显改善症状,减少急性发作。

Efficacy Observation on Inhalation Treatment with Seretide inhalation for Cases of Moderate and Severe COPD

Objective To observe the effects of seretide （salmeterol and fluticasone propionate） powder inhalants （50/500μg） inchronic obstructive pulmonary disease （COPD） during the mitigation. Methods In the treatment of moderate and severe 46 patientswith COPD in the Department of Respiratory Diseases in our hospital, the patients were randomly divided into treatment and controlgroup. The control group was given Aminophylline Sustained-release Tablets 0.2, bid, and Salbutamol Aerosol 2-3 puff, tid, while
the treatment group was given the aspiration for seretide（50/500μ g）, 1 puff, bid. Results During the period of observation, the clinical symptom and lung function were significantly improved more than those of the control group （P〈0.05）, meanwhile the number of acute exacerbation of COPD was obviously lower than the control group. Conclusions Seretide in the treatment of moderate and severe COPD during the mitigation can reduce the number of acute exacerbation of COPD, enhance patients with lung function, and has obvious improvement of their clinical symptom.